Neutral, CSF-Penetrant TTR Stabilizers Designed with Heterocyclic Linkers
- A new series of neutral, heterocyclic-linker-containing transthyretin (TTR) stabilizers is designed for improved brain and cerebrospinal fluid (CSF) penetration.
- Aims to address CNS/leptomeningeal manifestations of hereditary ATTR amyloidosis, where existing acidic stabilizers such as tafamidis show limited CNS exposure.
- Heterocyclic linker modifications reduced compound acidity relative to earlier chemotypes while reportedly preserving TTR tetramer-stabilizing potency and selectivity in vitro.
💡 Points
Finally—someone attacking the acidic-pharmacophore/P-gp efflux tradeoff head-on instead of just tolerating tafamidis's CNS blind spot. Ditching the carboxylic acid for heterocyclic linkers while holding onto tetramer-stabilizing potency is the hard part of this SAR, not the easy part. If CSF exposure holds up in vivo, leptomeningeal ATTR patients finally get a real option instead of an afterthought.